FIELD: biotechnology.
SUBSTANCE: invention relates to hybrid proteins based on fragments of fluorescent proteins and target therapeutic polypeptides, and can be used to express and obtain the target polypeptide. A fusion protein construct is proposed that contains fragments of fluorescent proteins and a target therapeutic polypeptide selected from human insulin precursor protein, insulin lispro precursor protein, insulin glargine precursor protein, glucagon-like peptide and its derivatives exenatide and liraglutide, insulin, calcitonin, teduglutide.
EFFECT: invention provides an increase in the efficiency of obtaining said target therapeutic polypeptides.
10 cl, 5 dwg, 1 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AMINOACIL-tRNA SYNTHASE, EFFECTIVE INTRODUCTION OF LYSINE DERIVATIVES | 2020 |
|
RU2790662C1 |
| INFLUENZA HEMAGGLUTININ COMPOSITIONS WITH HETEROLOGOUS EPITOPES AND/OR ALTERED CLEAVAGE SITES DURING MATURATION | 2017 |
|
RU2769406C2 |
| AMINOACIL-tRNA SYNTHASE FOR EFFECTIVE INTRODUCTION OF LYSINE DERIVATIVE INTO PROTEIN | 2020 |
|
RU2799794C2 |
| POLYFUNCTIONAL PROTEIN MOLECULES CONTAINING DECORIN AND USE THEREOF | 2019 |
|
RU2823357C2 |
| PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF HEPATITIS, LIVER FIBROSIS AND LIVER CIRRHOSIS, INCLUDING FUSION PROTEINS | 2017 |
|
RU2795548C2 |
| NPP1 FUSION PROTEINS | 2011 |
|
RU2760943C2 |
| NEW MODIFIED IMMUNOGLOBULIN Fc-FRAGMENT FUNCTION PROTEIN AND ITS USE | 2020 |
|
RU2800919C2 |
| ORAL CARE PRODUCTS AND METHODS CONTAINING HYDROXYAPATITE-BINDING PROTEINS | 2016 |
|
RU2745996C2 |
| PROTEINS WITH A DOUBLE FUNCTION AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM | 2016 |
|
RU2741345C2 |
| GLYCOSYLATED FUSED PROTEINS VWF WITH IMPROVED PHARMACOKINETICS | 2017 |
|
RU2782212C2 |
